Managing ulcerative colitis means finding the right combination of medication, dietary adjustments, and ongoing monitoring to keep inflammation under control and prevent flares. Most people achieve remission with medication alone, and only about 10% need surgery within the first decade after diagnosis. The specifics of your management plan depend on how severe your disease is, how much of your colon is affected, and how your body responds to treatment.
Medications That Control Inflammation
Drug therapy is the backbone of ulcerative colitis management, and it works in two phases: inducing remission (stopping an active flare) and maintaining remission (keeping things quiet long-term). The medications used for each phase often differ, and your treatment will likely evolve over time as your disease changes.
For mild to moderate disease, most people start with a class of anti-inflammatory drugs called 5-ASAs. These suppress acute flares and help extend periods of remission. They come in oral tablets, enemas, and suppositories, and many people with milder disease stay on them indefinitely.
When a flare is more severe, corticosteroids are used to bring inflammation down quickly. They reduce immune cell activity in the gut lining and can be very effective at inducing remission. But they don’t prevent future flares and carry significant side effects with long-term use, so the goal is always to taper off them as soon as possible.
If 5-ASAs aren’t enough to maintain remission, or if you find yourself needing repeated courses of steroids, your doctor will typically move to immunomodulators or biologics. Immunomodulators dampen the broader immune response and are often used when other treatments have failed or when steroid dependence becomes a problem. Biologics are more targeted: the most established ones block a specific inflammatory protein called TNF-alpha. Infliximab, for example, is recommended as a first-line rescue therapy for acute severe flares that don’t respond to steroids.
Newer Treatment Options
The treatment landscape has expanded significantly in recent years. Two newer classes of drugs, JAK inhibitors and IL-23 inhibitors, have changed how moderate to severe disease is managed.
IL-23 inhibitors, including mirikizumab, guselkumab, and risankizumab, selectively block a specific immune signaling pathway that drives gut inflammation. In a pooled analysis of six clinical trials involving over 3,600 patients, these drugs were roughly 2.5 times more likely to achieve clinical remission during the initial treatment phase compared to placebo. JAK inhibitors, particularly upadacitinib, have ranked among the most effective options for both inducing and maintaining remission, outperforming many existing biologics in head-to-head comparisons for clinical remission, visible healing of the colon lining, and deeper tissue-level healing.
The 2024 American Gastroenterological Association guidelines now position both IL-23 inhibitors and JAK inhibitors as high-efficacy options for patients who are new to biologic therapy and for those who haven’t responded to previous biologics.
Eating During Flares vs. Remission
There’s no single diet that treats ulcerative colitis, but what you eat can make a real difference in how you feel, especially during active flares. The general principle: simplify your diet when things are bad, and broaden it when things are calm.
During a flare, the goal is to minimize irritation to an already inflamed colon. That means limiting added fats and oils to around eight teaspoons per day and focusing on liquid oils rather than solid fats. You’ll want to keep up your calcium and vitamin D intake through sources like low-fat milk, lactose-free milk, fortified plant milks, or yogurt. Fortified pea milk and soy milk are higher in protein but can cause gas and bloating for some people.
Once your symptoms improve and you enter remission, you can gradually reintroduce fiber and whole grains. This is also a good time to increase omega-3 fatty acids, either through fatty fish like salmon and sardines or through fish oil or flaxseed oil supplements. The key word is “gradually.” Reintroducing high-fiber foods too quickly after a flare can trigger symptoms even when underlying inflammation has improved.
The Role of Probiotics
Probiotics occupy an interesting space in ulcerative colitis management. Several specific strains have shown real promise for helping maintain remission, though the evidence doesn’t yet support their ability to induce remission during active flares.
The strongest evidence exists for a multi-strain formulation called VSL#3 and for specific strains of Lactobacillus, including Lactobacillus GG and Lactobacillus reuteri. In small studies, VSL#3 maintained remission effectively over a full year, and Lactobacillus GG proved both effective and safe over 12 months at maintaining quiet disease. A non-pathogenic strain of E. coli called Nissle 1917 also showed remission-maintaining effects over 12 months in a study of 162 patients. European nutrition guidelines for inflammatory bowel disease specifically recommend VSL#3 and Lactobacillus reuteri for mild to moderate disease.
That said, not all probiotic strains work equally. A study using Lactobacillus acidophilus and Bifidobacterium lactis found no significant benefit over placebo for people in remission. Probiotics are best considered as an add-on to standard medication, not a replacement. China’s treatment guidelines formally recommend Bifidobacterium and Lactobacillus strains as adjuvant therapy alongside conventional drugs for mild to moderate disease.
Tracking Inflammation Between Colonoscopies
One of the trickiest aspects of managing ulcerative colitis is that you can feel fine while silent inflammation continues damaging your colon. This is where a stool test called fecal calprotectin becomes valuable. It measures a protein released by white blood cells in the gut, and higher levels indicate more active inflammation.
For ulcerative colitis, a fecal calprotectin level between roughly 112 and 172 micrograms per gram can identify both visible healing of the colon lining and deeper tissue-level healing, with accuracy ranging from about 82% to 87%. If your level consistently stays below this range, it’s a strong signal that your current treatment is working well. Levels above this range may indicate that your colon hasn’t fully healed even if your symptoms are manageable, which is important because ongoing inflammation raises your long-term risk of complications.
Colorectal Cancer Screening
Longstanding ulcerative colitis increases your risk of colorectal cancer, and regular surveillance colonoscopies are a critical part of long-term management. How often you need them depends on several factors: how long you’ve had the disease, how much of your colon is involved, whether you have ongoing inflammation, and whether you have a family history of colorectal cancer.
The American College of Gastroenterology recommends surveillance every one to three years for anyone with ulcerative colitis extending beyond the rectum, with adjustments based on your individual risk profile. If you also have a liver condition called primary sclerosing cholangitis, which is associated with ulcerative colitis in some people, you need annual colonoscopies regardless of other factors. A first-degree relative with colorectal cancer, ongoing active inflammation, or anatomic changes like strictures or pseudopolyps all push the recommended frequency toward the more frequent end of the range.
British guidelines take a more stratified approach, spacing surveillance as far apart as every five years for people with extensive colitis that shows no active inflammation, every three years for intermediate risk, and annually for higher-risk patients. The takeaway across all major guidelines: the more risk factors you have, the more frequently you need screening.
When Surgery Becomes Necessary
About 3% of people with ulcerative colitis require surgery within the first year of diagnosis, typically due to a severe flare that doesn’t respond to medication. That number rises to about 5% by five years and 10% by ten years. Surgery rates have been declining over the past two decades as biologic and newer targeted therapies have improved.
The standard operation removes the entire colon and rectum, then creates an internal pouch from the small intestine that connects to the anus, allowing you to have bowel movements without a permanent external bag. This procedure is considered curative since removing the colon eliminates the disease.
However, it comes with its own set of challenges. The most common complication is pouchitis, an inflammation of the newly created internal pouch. Within two years of surgery, about 48% of patients develop at least one episode. For most (roughly 29%), it’s a single isolated episode that responds to a short course of antibiotics. But about 19% develop recurrent pouchitis, which tends to require more medical visits and sometimes new immunosuppressive medications. About 40% of patients who develop pouchitis end up needing some form of immune-suppressing therapy. The need for complete pouch removal is rare, occurring in only about 1% of cases within two years. Roughly 9% of patients receive a new diagnosis of Crohn’s disease after the procedure, which can affect the pouch and complicate recovery.
Building a Long-Term Routine
The most effective management approach combines consistent medication with lifestyle habits that reduce your flare risk. Stress doesn’t cause ulcerative colitis, but it can trigger flares in people who already have it. Regular physical activity, adequate sleep, and stress management techniques are all associated with longer remission periods.
Staying on your maintenance medication even when you feel well is one of the most important things you can do. Stopping medication during remission is one of the most common reasons for relapse. Regular fecal calprotectin testing, typically every three to six months during stable remission, helps you and your doctor catch rising inflammation before it becomes a full-blown flare. Colonoscopy surveillance on the schedule appropriate for your risk level protects against the long-term cancer risk that comes with chronic colon inflammation.
Ulcerative colitis is a lifelong condition, but the majority of people achieve and maintain remission with the right treatment strategy. The options available today are broader and more effective than they were even five years ago, and the approach can be adjusted as your disease evolves.